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Urinary tract infection (UTI) is a common type of infectious disease globally.
The aim of this study was to detect the frequency of fosA3 and fosC2 genes in
extended-spectrum β-lactamases (ESBL) and blaDHA, blaCMY-2, and blaCMY-42 genes
in AmpC β-lactamases-producing isolates of Escherichia coli. In total, 120 isolates of
E. coliwere collected from three teaching hospitals between March 2014 and February
2015. Antibiotic susceptibility tests were carried out by disk diffusion method. The
presence of blaCMY-2, blaCMY-42, blaDHA, fosA3, and fosC2 genes was detected by
polymerase chain reaction (PCR) and sequencing. Of the 120 strains, 92 (76.6%) were
identiﬁed as ESBL producers, 30 (25%) were determined as AmpC β-lactamase
producers, and 24 (20%) had both ESBL and AmpC β-lactamase enzymes. Imipenem,
fosfomycin, and nitrofurantoin had the best effect against isolates of E. coli. PCR assay
demonstrated that the frequency of blaCMY-2, blaCMY-42, and blaDHA genes among
AmpC β-lactamases-producing strains were 39%, 1%, and 17.5%, respectively. This
study reports the ﬁrst detection of fosfomycin resistance in Iran. This study indicated
the increasing prevalence of UTI isolates of E. coli-harboring ESBL and AmpC
β-lactamases genes in Iran. Therefore, due to the high rate of blaDHA and blaCMY genes
and emergence of fosfomycin-resistant E. coli isolates, we recommend continuous
monitoring of antibiotic resistance as well as attention to guidelines of infection
controls.
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Introduction
Urinary tract infection (UTI) with approximately 200 million cases per year
is one of the most common types of infectious disease globally. It is estimated that
5% of men and 45% of women will be infected with UTI at least once during their
lifetime. UTIs are major contributors to global antibiotic use and resistance, due to
their high incidence rate. Many urological methods would carry high risk, without
effective drugs against common uropathogens [1–4]. Escherichia coli is the most
common uropathogen associated with UTIs in the world. A main increase in the
prevalence of extended-spectrum β-lactamase (ESBL)- and AmpC β-lactamase-
producing clinical strains of E. coli has been reported in the last decades [5, 6].
ESBLs and AmpC β-lactamases are the most frequently detected groups of
β-lactam ring hydrolyzing enzymes in UTI isolates of E. coli worldwide. Both are
the main causes of treatment failure in patients when they are produced by
pathogen [7–10]. Plasmid-mediated AmpC enzymes, such as CMY- and DHA-
type β-lactamases, have been reported in clinical isolates of E. coli. Due to the
plasmid-mediated characterization, which enables them to spread very rapidly, a
rapid development of resistance to AmpC genes has been observed in UTI isolates
of E. coli worldwide [11, 12]. Fosfomycin is one of the ﬁrst-line drugs recom-
mended for patients with UTIs, due to its activity against ESBL-producing and
ﬂuoroquinolone-resistant E. coli [13]. Fosfomycin resistance rates in UTI isolates
of E. coli are often lower than 10% but are higher than 30% when ESBL producers
are considered [14]. Recently, plasmid-mediated fosfomycin resistance genes
fosA3 and fosC2 emerged in E. coli clinical and non-clinical strains [15]. The
most prevalent gene is fosA3 that has been mainly detected in clinical isolates of E.
coli in Asian countries [13, 16–18] and fosC2 is found in the fragment cloned from
the conjugative plasmid of E. coli strain C316 [19]. The purpose of this study was
to identify the extended-spectrum- and AmpC β-lactamases-producing clinical
isolates of E. coli isolated from patients with UTIs and to detect the frequency of
fosA3 and fosC2 genes in ESBLs-producing strains and blaDHA, blaCMY-2, and
blaCMY-42 genes in AmpC β-lactamases-producing strains.
Materials and Methods
Clinical isolates
This study was a descriptive investigation. A total of 120 unduplicated UTI
isolates of E. coli were collected from Labbaﬁnejad, Shohada Tajrish, and
Taleghani Hospitals between March 2014 and February 2015. E. coli strains
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were identiﬁed by classical bacteriological and biochemical tests, such as triple
sugar iron, motility, methyl red, Voges–Proskauer, ornithine decarboxylation, and
lysine decarboxylation [20].
Susceptibility testing
Susceptibility testing to 11 antibiotics (Mast Group, Merseyside, UK) was
carried out by disk diffusion method according to recommendations of the Clinical
and Laboratory Standards Institute (CLSI) [21]. The antibiotics tested were as
follows: cefoxitin (30 μg), levoﬂoxacin (10 μg), gentamicin (10 μg), amikacin
(30 μg), cefotaxime (30 μg), tobramycin (10 μg), ampicillin (10 μg), fosfomycin
(10 μg), imipenem (10 μg), cefpodoxime (30 μg), nitrofurantoin (300 μg),
ciproﬂoxacin (10 μg), ceftriaxone (10 μg), ceftazidime (30 μg), and cotrimoxazole
(25 μg). E. coli ATCC 25922 was used as a control strain.
ESBL conﬁrmatory test
ESBL-producing UTI isolates of E. coli were detected by screening with
30 μg cefotaxime disk and then further testing with cefotaxime/clavulanic acid
disks to detect clavulanic acid enhancement ≥5 mm. Similarly, for conﬁrmation of
detection of ESBL-producing isolates, screening was performed using 30 μg
ceftazidime disk with and without clavulanic acid [11]. Klebsiella pneumoniae
ATCC 700603 was used as a control strain.
AmpC β-lactamase conﬁrmatory test
AmpC β-lactamase conﬁrmatory test was performed to detect AmpC-
producing UTI strains of E. coli. This test was performed by screening with
30 μg cefotaxime disk and then with cefotaxime/cloxacillin disks. Second
screening stage was performed using 30 μg ceftazidime disk with and without
cloxacillin [22].
Molecular detection of antibiotic resistance genes
The DNA was extracted by Roche Company and used as a template for
polymerase chain reaction (PCR). The master mix including 3 mmol/ml MgCl2
and 0.08 mmol/ml Taq polymerase was used (Sinclon Bioscience Company, Iran).
The presence of blaCMY-2, blaCMY-42, fosA3, fosC2, and blaDHA genes was
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determined for all UTI isolates of E. coli-harboring ESBLs and AmpC β-
lactamases by PCR technique (Bio Intellectica PCR). The primer sets and thermal
cycling conditions described in Tables I and II. One of the PCR products was
puriﬁed and direct sequencing was performed. Two negative controls (molecular
grade water) and positive control were included in each PCR run. KX342010,
KX342011, and KP696465.1 strains of E. coli harboring the blaCMY-2, blaCMY-42,
and blaDHA genes were conﬁrmed by sequencing method and were used as
positive controls.
Statistical analysis
Current survey was a descriptive study. Analysis of results was carried out
by MINITAB 16 software. The p value and conﬁdence intervals were <0.05% and
95%, respectively.
Results
Overall, 60 (50%) strains were isolated from Labbaﬁnejad Hospital, of
which 10 were related to dialysis patients, 25 (20.8%) strains were isolated from
Taleghani Hospital, of which 15 were related to dialysis patients and 35 (29.2%)
strains were isolated from Shohada Tajrish Hospital, of which 12 were related to
dialysis patients. Eighty-seven strains were isolated from female patients (72.5%)
and 33 from males (27.5%). The age range of the patients with UTIs was
2–70 years. The isolates were obtained from patients in different age groups:
2–5 years (N = 3), 6–18 years (N = 20), 19–40 years (N = 48), and 41–65 years
Table I. Primer sequence and product size
Primer Sequence (5′→3′) Gene
Product
size (bp) Reference
CMY-2-F ACGAAGAGGCAATGACCAGA blaCMY-2 451 This study
CMY-2-R CCAGTGGAGCCCGTTTTATG
CMY-42-F ACGAAGAGGCAATGACCAGA blaCMY-2 451 This study
CMY-42-R CCAGTGGAGCCCGTTTTATG
FOSA3-F CCTGGCATTTTATCAGCAGT fosA3 234 This study
FOSA3-R CGGTTATCTTTCCATACCTCAG
FOSC2-F TGGAGGCTACTTGGATTTG fosC2 217 This study
FOSC2-R AGGCTACCGCTATGGATTT
DHA-F TGTATGCAAACAGCAGTATC blaDHA 312 This study
DHA-R ACATTGCCATTTCCAGATCC
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(N = 42), and seven isolates were isolated from patients of more than 65 years
of age. The previous use of antibiotics, corticosteroids, or contraceptive pills is
shown in Figure 1. Of the 120 strains, 92 (76.6%) were identiﬁed as ESBL
producers, 30 (25%) were determined as AmpC β-lactamase producers, and 24
(20%) had both ESBL and AmpC β-lactamase enzymes (Table III). In this study,
imipenem, fosfomycin, and nitrofurantoin against clinical isolates of E. coli had
the best effect in antimicrobial susceptibility tests. The patterns of the antibiotic
susceptibility tests in E. coli isolates have been shown in Table IV. Screening of
antibiotic resistance genes, fosA3, fosC2, blaDHA, blaCMY-2, and blaCMY-42, by
PCR assay demonstrated that the frequency of blaCMY-2, blaCMY-42, and blaDHA
genes among AmpC β-lactamases-producing strains were 39%, 1%, and 17.5%
(21) isolates, respectively. To the best of our knowledge, this is the ﬁrst report of
emergence of blaCMY-42 genes in E. coli isolates in Iran. Among the blaCMY-
positive isolates, 12 strains and among the blaDHA-positive isolates, 6 strains were
isolated from dialysis patients. The nucleotide sequence data that reported in this
Figure 1. Previous use of antibiotics, corticosteroids, or contraceptive pills
Table III. Sources of E. coli isolates harboring ESBL and AmpC β-lactamases
β-lactamase enzymes
Hospitals
Total no. of isolatesLabbaﬁnejad Shohada Tajrish Taleghani
ESBL 48 24 20 92
AmpC 9 9 12 30
ESBL+AmpC 5 7 12 24
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study have been submitted to the GenBank sequence database and assigned
accession number KX342010 for blaCMY-2 gene, KX342011 for blaCMY-42 gene,
and KP696465.1 for blaDHA gene.
Discussion
UTIs, due to their high incidence rate, are one of the most important
contributors to global antibiotic resistance. This study was conducted to identify
the clinical isolates of E. coli isolated from patients with UTIs and detect drug
resistance genes in the extended-spectrum- and AmpC β-lactamases-harboring
strains. A main increase in the prevalence of ESBL- and AmpC β-lactamase-
producing strains of E. coli has been reported in the last decades. In current survey,
the prevalence of ESBL- and AmpC β-lactamase producers were identiﬁed 76.6%
and 25%, respectively. This high prevalence of resistance to broad-spectrum
β-lactams is a global threat. Uncontrolled use of broad-spectrum drugs, less
relation between physicians and laboratories, and lack of attention to laboratory
screening of ESBL and AmpC β-lactamase production by clinical isolates E. coli
are the most important risk factors for this high rate of drug resistance. The patterns
of the antibiotic susceptibility tests demonstrated that imipenem, fosfomycin, and
nitrofurantoin had the best effect against E. coli isolates in our investigation.
Although fosfomycin was one of the best drugs, 8 (6.6%) isolates were resistant to
this oldest and most effective drug for treatment of UTIs. Due to the few
Table IV. Antibiotic susceptibility testing results
Antibiotic Resistant no. (%) Sensitive no. (%) Intermediate no. (%)
Cefoxitin 80 (66.6) 40 (33.4) 0 (0)
Levoﬂoxacin 40 (33.4) 75 (62.5) 5 (4.1)
Gentamicin 62 (51.6) 46 (38.3) 12 (10)
Amikacin 15 (12.5) 75 (62.5) 30 (25)
Imipenem 7 (5.8) 113 (94.2) 0 (0)
Cefotaxime 87 (72.5) 33 (27.5) 0 (0)
Tobramycin 88 (73.3) 32 (26.6) 0 (0)
Ampicillin 120 (100) 0 (0) 0 (0)
Fosfomycin 8 (6.6) 112 (93.4) 0 (0)
Cefpodoxime 112 (93.4) 8 (6.6) 0 (0)
Nitrofurantoin 13 (10.8) 107 (89.2) 0 (0)
Ciproﬂoxacin 90 (75) 25 (20.8) 5 (4.2)
Ceftriaxone 86 (71.6) 34 (28.4) 0 (0)
Ceftazidime 65 (54.2) 55 (45.8) 0 (0)
Cotrimoxazole 95 (79.2) 25 (20.8) 0 (0)
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therapeutic choices for UTIs treatment, increasing rate of resistance to fosfomycin
can become a great concern around the world. Lob et al. [22] performed a study in
Canada and the United States on 3498 E. coli UTI isolates and conﬁrmed that
imipenem had the most susceptibility, more than 95%, against clinical strains of
E. coli. Plasmid-mediated CMY- and DHA-type β-lactamases have been reported
in E. coli isolates. This study showed that prevalence of blaCMY-2, blaCMY-42, and
blaDHA genes among AmpC β-lactamases producers were 39%, 1%, and 17.5%,
respectively. In a study carried out by Shayan et al. [23] in Iran, the prevalence of
blaCMY gene among 392 isolates of E. coli was investigated. They reported that 13
(3.3%) isolates were identiﬁed as AmpC producers, which 11 of the 13 isolates
contained the blaCMY gene. In another survey performed by Saffar et al. [24] in
Iran (Tehran), blaDHA gene was detected in 14.8% isolates of E. coli. Their results
conﬁrmed this hypothesis that geographical location plays the most important role
in the distribution of blaDHA gene, due to the closer regions have a relatively
similar distribution of blaDHA gene [24]. Recently, plasmid-mediated quinolone
resistance determinants have been also reported among E. coli isolates, further-
more, plasmid-mediated fosfomycin-modifying enzymes, fosA3 and fosC2, were
identiﬁed in E. coli clinical isolates. Acquisition of these fosfomycin resistance
determinants, which inactivate fosfomycin by exerting glutathione-S-transferase
activity, has also been seem to confer resistance [19, 25]. Although phenotypic test
reported eight isolates of E. coli as fosfomycin-resistant strains, molecular test
showed that none of them had the fosA3 or fosC2 genes. Our research was the ﬁrst
investigation in Iran about detection of fosfomycin resistance genes, fosA3 and
fosC2. Therefore, additional studies using PCR or a probe-based assay can
simplify the actual dissemination of these resistance genes. In conclusion, this
study demonstrated that UTI isolates of E. coli-harboring ESBL and AmpC
β-lactamases are increasing, which may lead to more cost and mortality
rate. Therefore, efforts must be undertaken to diagnose ESBL- and AmpC
β-lactamases-producing isolates to allow for targeted treatment. Furthermore, due
to the high rate of blaDHA and blaCMY genes and emergence of fosfomycin-
resistant E. coli isolates, we recommend continuous monitoring of antibiotic
resistance, attention to guidelines of infection controls, use of sensitive methods
for laboratory diagnosis, and close relation between physician and laboratories.
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